
#### PARTNERING with PATIENTS

# Oxytocin to Start or Advance Labour: 5 Questions to Ask



By: Alice Watt<sup>1</sup>, Lori Webel-Edgar<sup>2</sup>, Maryann Murray<sup>3</sup>, Joanna Noble<sup>2</sup>, Sylvia Hyland<sup>1</sup>, Laura Zahreddine<sup>4</sup>, Sharon Dore<sup>5</sup>, Ioana Popescu<sup>6</sup>, Douglas Doucette<sup>7</sup>, Abigail Corbin<sup>8</sup>, Jennifer Blake<sup>9</sup>

#### Aim

Co-develop, co-design and disseminate a national resource together with patients to facilitate informed dialogue for the **safe use of IV oxytocin.** 

### Description

Why Partner with Patients to focus on Oxytocin?
Oxytocin is a high-alert medication. When used to start or advance labour the administration of oxytocin has been identified as a high-risk area of practice. The mismanagement of IV oxytocin is HIROC's second highest ranked claim theme by litigation cost for acute organizations. Inadequate and inconsistent discussions with the pregnant person surrounding IV oxytocin is a common contributing factor in

### Initiative

related medical-legal claims.

To help mitigate these challenges, a resource was developed, led by ISMP Canada to support health care providers (HCPs) and pregnant individuals to start an informed conversation about the use of oxytocin to start or advance labour. The resource was developed by a pan-Canadian advisory panel of patients, families, HCPs, patient safety and other experts. Funded by the Canadian Medication Safety Coalition.

Mismanagement of IV oxytocin is the 2nd highest risk based on HIROC claims

https://www.hiroc.com/resources/report




Figure 1 - Oxytocin to Start or Advance Labour: 5 Questions to Ask - Patient Handout https://www.ismp-canada.org/oxytocinsafety/

"This patient
handout could open the
lines of communication between
patients and health care providers
and empower parents and carers to feel
in control of their birth story."

Christie, Patient Advocate

Christica Storm

Staff have liked the easy to read, easy to follow format. We have the document laminated and available to be handed to patients whenever they are prescribed oxytocin for induction or augmentation."

Winchester District Memorial Hospital

# Pathway to a Successful Patient & Provider Co-Designed Resource

- Performed an environmental scan, literature review, and multiincident analysis of oxytocin incidents.
- Established a pan-Canadian Advisory Panel to support the development of the resource and involved patients right from the start.
- Tested the resource with patients and HCPs, using a quality improvement approach.
- Revised the content and disseminated the resource nationally on World Patient Safety Day 2021.

## Pilot Testing Results and Spread

- Results of pan-Canadian testing (n=61),
- 100% of patients (n=15) and over 70% of HCPs (n=46) found this patient handout to be useful
- 78% of HCPs found the handout easy to understand.
- Reflections: language matters when discussing risks associated with IV oxytocin.
- Currently working with the International Medication Safety Network (IMSN) Special Interest Group on Oxytocin Safety and presented it for the World Health Organization.
- Endorsement from 12 organizations. Further dissemination and evaluation activities planned.